DiaMedica Therapeutics Company Insiders
| DMAC Stock | USD 2.60 0.23 9.70% |
DiaMedica Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding DiaMedica Therapeutics suggests that all insiders are extremely bullish. DiaMedica Therapeutics employs about 18 people. The company is managed by 19 executives with a total tenure of roughly 76 years, averaging almost 4.0 years of service per executive, having 0.95 employees per reported executive.
| Rick Pauls CEO President CEO, Director |
| Richard Pilnik Chairman Independent Chairman of the Board |
DiaMedica Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-06-23 | Scott Kellen | Acquired 10000 @ 3.91 | View |
Monitoring DiaMedica Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
DiaMedica |
DiaMedica Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with DiaMedica Therapeutics' future performance. Based on our forecasts, it is anticipated that DiaMedica will maintain a workforce of about 18 employees by May 2024.DiaMedica Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3002) % which means that it has lost $0.3002 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4677) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 56.4 M, whereas Non Currrent Assets Other are forecasted to decline to (0.94).The current year's Common Stock Shares Outstanding is expected to grow to about 34.2 M, whereas Net Loss is projected to grow to (11.6 M).
DiaMedica Therapeutics Workforce Comparison
DiaMedica Therapeutics is one of the top stocks in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 32,844. DiaMedica Therapeutics adds roughly 18.0 in number of employees claiming only tiny portion of equities under Health Care industry.
DiaMedica Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DiaMedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on DiaMedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, DiaMedica Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-06-01 | 20.0 | 20 | 1 | 2,765,711 | 15,000 |
| 2023-03-01 | 5.0 | 5 | 1 | 151,440 | 0.00 |
| 2022-12-01 | 11.0 | 11 | 1 | 3,060,847 | 2,855,847 |
| 2022-03-01 | 7.0 | 7 | 1 | 391,743 | 0.00 |
| 2019-03-01 | 1.0 | 1 | 1 | 150.00 | 150.00 |
| 2018-12-01 | 0.1633 | 8 | 49 | 31,250 | 507,520 |
DiaMedica Therapeutics Notable Stakeholders
A DiaMedica Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DiaMedica Therapeutics often face trade-offs trying to please all of them. DiaMedica Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DiaMedica Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Dietrich MBA | CEO President | Profile | |
| Rick Pauls | President CEO, Director | Profile | |
| Richard Pilnik | Independent Chairman of the Board | Profile | |
| Paul Papi | Vice President - Business Development | Profile | |
| Scott CPA | CFO Secretary | Profile | |
| Scott Kellen | CFO, Corporate Secretary | Profile | |
| James Parsons | Director | Profile | |
| Jerry Xiao | Director | Profile | |
| Michael Giuffre | Independent Director | Profile | |
| Harry Alcorn | Director | Profile | |
| Ambarish Shah | Chief Officer | Profile | |
| Julie CCRP | Senior Operations | Profile | |
| Dominic Cundari | Chief Officer | Profile | |
| David Wambeke | Chief Officer | Profile | |
| Todd Verdoorn | Chief Scientific Officer | Profile | |
| MS MD | Independent Consultant | Profile | |
| Scott CA | CFO Sec | Profile | |
| Edward Calamai | Consulting Manufacturing | Profile | |
| Lorianne MD | Chief Officer | Profile |
About DiaMedica Therapeutics Management Performance
The success or failure of an entity such as DiaMedica Therapeutics often depends on how effective the management is. DiaMedica Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DiaMedica management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DiaMedica management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.38) | (0.40) |
The data published in DiaMedica Therapeutics' official financial statements usually reflect DiaMedica Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DiaMedica Therapeutics. For example, before you start analyzing numbers published by DiaMedica accountants, it's critical to develop an understanding of what DiaMedica Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of DiaMedica Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DiaMedica Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DiaMedica Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DiaMedica Therapeutics. Please utilize our Beneish M Score to check the likelihood of DiaMedica Therapeutics' management manipulating its earnings.
DiaMedica Therapeutics Workforce Analysis
Traditionally, organizations such as DiaMedica Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DiaMedica Therapeutics within its industry.DiaMedica Therapeutics Manpower Efficiency
Return on DiaMedica Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 1M | |
| Working Capital Per Employee | 2.8M | |
| Working Capital Per Executive | 2.7M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Return On Assets (0.30) | Return On Equity (0.47) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.